Focus shifts to SID meeting on May 14 for biomarker data that could support soquelitinib's differentiated profile. No near-term revenue catalysts. Monitor Phase 2 AD enrollment updates.
Price Chart
Executive Summary
Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M ($0.15/share), slightly missing consensus of $0.14 loss. The miss is marginal and overshadowed by positive pipeline progress: soquelitinib Phase 2 AD trial initiation, ongoing Phase 3 PTCL enrollment, and upcoming SID data presentation on May 14.
Key Financial Metrics
Key Facts
- Net loss per share $0.15 vs consensus $0.14 (7.1% miss)
- Cash, cash equivalents and marketable securities $236.7M as of March 31, 2026
- Phase 2 atopic dermatitis trial initiated in Q1 2026
- Registrational Phase 3 PTCL trial enrollment continues
- New soquelitinib data to be presented at SID Annual Meeting May 13-16, 2026
Financial Impact
EPS $0.01 miss on $0.14 consensus is marginal; no revenue impact for pre-revenue biotech
Risk Factors
- Clinical trial failure or delays
- Dilution risk from future financing (cash runway to Q2 2028)
- No approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003154 |
| Document: f8k_050726.htm | 0001171843-26-003154 |
| Document: 0001171843-26-003154-index-headers.html | 0001171843-26-003154 |
| Document: 0001171843-26-003154-index.html | 0001171843-26-003154 |
| Document: 0001171843-26-003154.txt | 0001171843-26-003154 |
| 8-K Data (Synthetic) | 0001171843-26-003154 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Institutional Cluster | $14.46 $12.42 | ▼ −14.11% | ▼ −13.58% | $10.90 (−24.62%) |
Jul 22, 2026 10w ago | 8-K | $13.68 $14.33 | ▲ +4.75% | ▲ +1.44% | $10.90 (−20.32%) |
Jun 11, 2026 16w ago | Institutional Cluster | $11.60 $16.20 | ▲ +39.66% | ▲ +37.76% | $10.90 (−6.03%) |
May 14, 2026 20w ago | 8-K | $13.66 $11.93 | ▼ −12.63% | ▼ −11.77% | $10.90 (−20.18%) |
May 7, 2026 21w ago | 8-K | $15.55 $11.12 | ▼ −28.49% | ▼ −28.51% | $10.90 (−29.90%) |
Apr 24, 2026 23w ago | DEFA14A | $15.92 $12.83 | ▼ −19.41% | ▼ −24.37% | $10.90 (−31.53%) |
Apr 21, 2026 23w ago | Press Release | $17.14 $12.21 | ▼ −28.76% | ▼ −33.68% | $10.90 (−36.41%) |
Mar 12, 2026 29w ago | Press Release | $15.32 $15.17 | ▼ −0.98% | ▼ −4.57% | $10.90 (−28.85%) |
Mar 5, 2026 30w ago | Press Release | $15.80 $14.71 | ▼ −6.87% | ▼ −4.82% | $10.90 (−30.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access